Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

Wnt signalling pathway inhibitor

DRUG CLASS:

Wnt signalling pathway inhibitor

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

CTNNB1 mutation	Endometrial Cancer	CTNNB1 mutation	Endometrial Cancer	PRI724 + SM04690 Sensitive: B - Late Trials PRI724 + SM04690 Sensitive : B	PRI724 + SM04690 Sensitive: B - Late Trials PRI724 + SM04690 Sensitive : B
CTNNB1 mutation	Endometrial Cancer	CTNNB1 mutation	Endometrial Cancer	SM04690 Sensitive: B - Late Trials SM04690 Sensitive : B	SM04690 Sensitive: B - Late Trials SM04690 Sensitive : B
6-gene WNT pathway signature	HER2 Negative Breast Cancer	6-gene WNT pathway signature	HER2 Negative Breast Cancer	OMP-18R5 Sensitive: C3 – Early Trials OMP-18R5 Sensitive : C3	OMP-18R5 Sensitive: C3 – Early Trials OMP-18R5 Sensitive : C3
RSPO3 fusion	Gastric Cancer	RSPO3 fusion	Gastric Cancer	pembrolizumab + CGX1321 Sensitive: C3 – Early Trials pembrolizumab + CGX1321 Sensitive : C3	pembrolizumab + CGX1321 Sensitive: C3 – Early Trials pembrolizumab + CGX1321 Sensitive : C3
CTNNB1 expression	Hepatocellular Cancer	CTNNB1 expression	Hepatocellular Cancer	PRI724 Sensitive: D – Preclinical PRI724 Sensitive : D	PRI724 Sensitive: D – Preclinical PRI724 Sensitive : D
NOTCH1 mutation	Squamous Cell Carcinoma of Head and Neck	NOTCH1 mutation	Squamous Cell Carcinoma of Head and Neck	WNT974 Sensitive: D – Preclinical WNT974 Sensitive : D	WNT974 Sensitive: D – Preclinical WNT974 Sensitive : D
NOTCH1 C478F	Squamous Cell Carcinoma of Head and Neck	NOTCH1 C478F	Squamous Cell Carcinoma of Head and Neck	WNT974 Sensitive: D – Preclinical WNT974 Sensitive : D	WNT974 Sensitive: D – Preclinical WNT974 Sensitive : D
RBMS3 deletion	Ovarian Cancer	RBMS3 deletion	Ovarian Cancer	PRI724 Sensitive: D – Preclinical PRI724 Sensitive : D	PRI724 Sensitive: D – Preclinical PRI724 Sensitive : D
BOP1 overexpression	Triple Negative Breast Cancer	BOP1 overexpression	Triple Negative Breast Cancer	PRI724 Sensitive: D – Preclinical PRI724 Sensitive : D	PRI724 Sensitive: D – Preclinical PRI724 Sensitive : D
ARSI overexpression	Squamous Cell Carcinoma of Head and Neck	ARSI overexpression	Squamous Cell Carcinoma of Head and Neck	XAV-939 Sensitive: D – Preclinical XAV-939 Sensitive : D	XAV-939 Sensitive: D – Preclinical XAV-939 Sensitive : D
Chr inv(3)t(3;3) + MECOM overexpression	Acute Myelogenous Leukemia	Chr inv(3)t(3;3) + MECOM overexpression	Acute Myelogenous Leukemia	venetoclax + BC2059 Sensitive: D – Preclinical venetoclax + BC2059 Sensitive : D	venetoclax + BC2059 Sensitive: D – Preclinical venetoclax + BC2059 Sensitive : D
Chr inv(3)t(3;3) + MECOM overexpression	Acute Myelogenous Leukemia	Chr inv(3)t(3;3) + MECOM overexpression	Acute Myelogenous Leukemia	OTX015 + BC2059 Sensitive: D – Preclinical OTX015 + BC2059 Sensitive : D	OTX015 + BC2059 Sensitive: D – Preclinical OTX015 + BC2059 Sensitive : D
TNIK overexpression	Lung Non-Small Cell Squamous Cancer	TNIK overexpression	Lung Non-Small Cell Squamous Cancer	NCB-0846 Sensitive: D – Preclinical NCB-0846 Sensitive : D	NCB-0846 Sensitive: D – Preclinical NCB-0846 Sensitive : D
CTNNB1 S45P	Hepatocellular Cancer	CTNNB1 S45P	Hepatocellular Cancer	PRI724 Sensitive: D – Preclinical PRI724 Sensitive : D	PRI724 Sensitive: D – Preclinical PRI724 Sensitive : D